Strongbridge Biopharma (NASDAQ:SBBP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday, Zacks.com reports. The firm currently has a $5.25 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 14.38% from the stock’s previous close.
According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
A number of other research firms also recently weighed in on SBBP. ValuEngine upgraded Strongbridge Biopharma from a “sell” rating to a “hold” rating in a research report on Monday, March 25th. Oppenheimer set a $15.00 price objective on Strongbridge Biopharma and gave the stock a “buy” rating in a research note on Tuesday, March 26th. BidaskClub raised Strongbridge Biopharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 2nd. Cantor Fitzgerald set a $12.00 price objective on Strongbridge Biopharma and gave the stock a “buy” rating in a research note on Tuesday, February 26th. Finally, Laidlaw began coverage on Strongbridge Biopharma in a research note on Tuesday, December 18th. They set a “buy” rating and a $11.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $13.32.
Strongbridge Biopharma (NASDAQ:SBBP) last released its earnings results on Tuesday, February 26th. The biotechnology company reported $1.64 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $2.14. The company had revenue of $4.51 million during the quarter, compared to the consensus estimate of $5.03 million. Strongbridge Biopharma had a return on equity of 108.51% and a net margin of 176.69%. On average, equities research analysts expect that Strongbridge Biopharma will post -1.52 earnings per share for the current year.
A number of large investors have recently bought and sold shares of SBBP. Stifel Financial Corp acquired a new position in Strongbridge Biopharma in the fourth quarter valued at about $73,000. Citadel Advisors LLC acquired a new position in Strongbridge Biopharma in the third quarter valued at about $157,000. Tibra Equities Europe Ltd acquired a new position in Strongbridge Biopharma in the first quarter valued at about $324,000. Marshall Wace LLP acquired a new position in Strongbridge Biopharma in the third quarter valued at about $1,290,000. Finally, D. E. Shaw & Co. Inc. grew its stake in Strongbridge Biopharma by 89.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 355,874 shares of the biotechnology company’s stock valued at $1,594,000 after acquiring an additional 168,243 shares during the period. 49.10% of the stock is owned by hedge funds and other institutional investors.
About Strongbridge Biopharma
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
Read More: Bid-Ask Spread
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.